Blackstone Life Sciences Announces $455 Million Collaboration With Boston Scientific

What happened

Blackstone Life Sciences announced a $455 million collaboration with Boston Scientific. The two companies will co-fund development of Boston Scientific's Vitalyst heart pump for patients with cardiogenic shock.

Confirmed

Global impact / market context

Boston Scientific gains outside money to help pay for development costs, which reduces the cash it must spend itself. Blackstone receives a stake in a medical device program, tying its return to whether the heart pump reaches patients.

Analyst inference

Large investment firms are putting money into specific drug and device programs through deals that share development costs. Such deals let device makers spread risk, while showing investors see health care innovation as a source of steady, long-term fees.

Analyst inference

What to watch

1. Watch for details on when the Vitalyst heart pump could reach the market and how the two companies share costs and any future revenue. Confirmed
2. Watch whether Boston Scientific adds other co-funding partners for this heart pump or for similar devices in its development pipeline. Proposed
3. Watch whether this deal leads other medical device makers to seek outside capital for costly development programs, a sign of changing funding habits. Analyst inference

Evidence

• Original source link unavailable